Gliomas with comutations of isocitrate dehydrogenase (IDH) genes and telomerase reverse transcriptase (TERT) gene promoter (IDHmut pTERTmut) show distinct biological features and respond to first‐line treatment differently in comparison with other gliomas. The gene discussed is IDH3A; the disease is central nervous system cancer.